Skip to main content

20 August 2021

Gene therapy: AAV

Download PDF – 1.4 MB

AAV - Production platforms for gene therapy development

Licensable AAV production platforms

Efficient, scalable and cost-effective platforms for vector engineering

OXGENE helps solve the challenge of scalable manufacture for gene therapy.

Our GMP-compliant solutions accelerate the development of novel therapeutics, ensuring consistent quality of rAAV vectors and minimising risk during the product development lifecycle.

Resource updated on 18/2/2021

Download the resource to continue reading.
×